Your Good Partner in Biology Research

  1. 首頁
  2. 試劑盒
  3. 酶聯(lián)免疫試劑盒
  4. Human A Disintegrin And Metalloprotease 9,ADAM9 ELISA Kit

Human A Disintegrin And Metalloprotease 9,ADAM9 ELISA Kit

  • 中文名稱：
    人解整合素樣金屬蛋白酶9(ADAM9)酶聯(lián)免疫試劑盒
  • 貨號：
    CSB-E11904h
  • 規(guī)格：
    96T/48T
  • 價格：
    ￥3200/￥2500
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：

    The ELISA Kit is designed for quantitatively measuring human ADAM9 levels in samples, including serum, plasma, tissue homogenates, cell culture supernates, or ascitic fluid. It uses the sandwich enzyme immunoassay technique in combination with the enzyme-substrate chromogenic reaction to quantify the analyte in the sample. The color develops positively to the amount of ADAM9 in samples. The color intensity is measured at 450 nm via a microplate reader.

    ADAM9 is a metzincin cell-surface protease involved in several biological processes such as myogenesis, fertilization, cell migration, inflammatory response, proliferation, and cell-cell interactions. It is involved in inflammation, degenerative diseases, and cancer. In inflammation, ADAM9 contributes to monocyte fusion, mediating the conversion of monocytes-macrophages to multinucleated giant cells (MGCs) in response to foreign bodies or bacteria. The generated granulomatous lesions help to isolate the pathogens and also enhance phagocytotic activity. ADAM9 has been found over-expressed in several solid tumors such as glioma, melanoma, prostate cancer, pancreatic ductal adenocarcinoma, as well as gastric, breast, lung, and liver cancers. Upregulation of ADAM9 is associated with tumor aggressiveness and poor prognosis.

  • 別名：
    ADAM 9 ELISA Kit; ADAM metallopeptidase domain 9 ELISA Kit; Adam9 ELISA Kit; ADAM9_HUMAN ELISA Kit; Cellular disintegrin-related protein ELISA Kit; Cone rod dystrophy 9 ELISA Kit; CORD9 ELISA Kit; Disintegrin and metalloproteinase domain-containing protein 9 ELISA Kit; MCMP ELISA Kit; MDC9 ELISA Kit; Meltrin-gamma ELISA Kit; Metalloprotease/disintegrin/cysteine-rich protein 9 ELISA Kit; Mltng ELISA Kit; Myeloma cell metalloproteinase ELISA Kit
  • 縮寫：
  • Uniprot No.：
  • 種屬：
    Homo sapiens (Human)
  • 樣本類型：
    serum, plasma, tissue homogenates, cell culture supernates, ascitic fluid
  • 檢測范圍：
    62.5 pg/mL-4000 pg/mL
  • 靈敏度：
    15.6 pg/mL
  • 反應(yīng)時間：
    1-5h
  • 樣本體積：
    50-100ul
  • 檢測波長：
    450 nm
  • 研究領(lǐng)域：
    Cancer
  • 測定原理：
    quantitative
  • 測定方法：
    Sandwich
  • 精密度：
    Intra-assay Precision (Precision within an assay): CV%<8%
    Three samples of known concentration were tested twenty times on one plate to assess.
    Inter-assay Precision (Precision between assays): CV%<10%
    Three samples of known concentration were tested in twenty assays to assess.
  • 線性度：
    To assess the linearity of the assay, samples were spiked with high concentrations of human ADAM9 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
    　SampleSerum(n=4)
    1:1Average %96
    Range %9-101
    1:2Average %87
    Range %84-92
    1:4Average %95
    Range %92-97
    1:8Average %93
    Range %89-99
  • 回收率：
    The recovery of human ADAM9 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
    Sample TypeAverage % RecoveryRange
    Serum (n=5) 9087-93
    EDTA plasma (n=4)9389-95
  • 標(biāo)準(zhǔn)曲線：
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
    pg/mlOD1OD2AverageCorrected
    40002.657 2.557 2.607 2.445
    20001.924 1.824 1.874 1.712
    10001.126 1.116 1.121 0.959
    5000.655 0.645 0.650 0.488
    2500.380 0.370 0.375 0.213
    1250.271 0.261 0.266 0.104
    62.50.215 0.212 0.214 0.052
    00.163 0.161 0.162 　
  • 數(shù)據(jù)處理：
  • 貨期：
    3-5 working days

產(chǎn)品評價

靶點(diǎn)詳情

  • 功能：
    Cleaves and releases a number of molecules with important roles in tumorigenesis and angiogenesis, such as TEK, KDR, EPHB4, CD40, VCAM1 and CDH5. May mediate cell-cell, cell-matrix interactions and regulate the motility of cells via interactions with integrins.; May act as alpha-secretase for amyloid precursor protein (APP).
  • 基因功能參考文獻(xiàn)：
    1. miR-129-5p suppressed cell proliferation and invasion ability through regulating ADAM9. PMID: 29879625
    2. Studies indicate that a disintegrin and a metalloprotease 9 (ADAM9) is involved in solid cancers with the different mechanisms which it employ to drive tumor progression [Review]. PMID: 29550974
    3. Collective results suggested that galangin may act as an effective chemotherapeutic agent for glioma cancer depending on its ability to bring about ADAM9 and Erk1/2 activation. PMID: 29115634
    4. miR-543 serves as a tumor suppressor in glioblastoma multiforme through ADAM9 regulation. PMID: 28849046
    5. Study demonstrates that diabetes-mediated decrease in miR-126 leads to a corresponding increase in its target, ADAM9, which in turn cleaves MERTK (inactivates downstream engulfment signaling), thus resulting in defective macrophage efferocytosis of apoptotic cardiomyocytes. PMID: 27827458
    6. These results revealed that ADAM9 down-regulates miR-1 via activating EGFR signaling pathways, which in turn enhances CDCP1 expression to promote lung cancer progression. PMID: 28537886
    7. These findings suggested that miR302a inhibited osteosarcoma cell growth and metastasis by targeting ADAM9. PMID: 28713950
    8. Data show that ADAM9 is over-expressed in an activated form in human ovarian clear cell carcinomas, and suggest that it plays a key role in cisplatin resistance. PMID: 29247567
    9. Mechanistic investigations found that quercetin suppressed Snail-dependent Akt activation by upregulating maspin and Snail-independent a disintegrin and metalloproteinase (ADAM) 9 expression pathways to modulate the invasive ability of NSCLC cells PMID: 28648644
    10. ADAM9 is a component of cell-cell junctions. ADAM9 must be expressed by both adjacent cells for cell junction localisation. ADAM9 can self-associate via its ectodomain. The soluble ADAM9 ectodomain inhibits monocyte-endothelial transmigration. PMID: 28928095
    11. hese results emphasize the critical influence of ADAM9 on lung cancer progression and aggressiveness. ADAM9 should at least be a marker of cancer aggressiveness and a potential therapeutic target for cancer treatment. PMID: 28675123
    12. MiR-126-ADAM9 pathway-based therapeutic targeting may represent a novel approach for the inhibition of hepatitis B virus-related hepatocellular carcinoma metastases. PMID: 28639884
    13. miR-520f inhibited tumor cell invasion by directly targeting ADAM9 and the TGFbeta receptor TGFBR2. PMID: 28209612
    14. The results suggest that ADAM9 mRNA expression is associated with tumor grade and histological type in gliomas and can serve as an independent prognostic factor, specifically in LGG patients. PMID: 27571068
    15. ADAM9 could possibly be regarded as a biomarker for GC diagnosis and prevention. Moreover, as directly targeted by miR-126 in GC, ADAM9 may be a potential target for GC therapeutic treatment which warrants intensive study PMID: 28260063
    16. ADAM9 is a direct target of miR-20b and that miR-20b decreased the 5-FU resistance of HCT116-R cells. PMID: 27878272
    17. the present study demonstrated the expression and clinical roles of miR-140 in glioma and suggested that miR-140 inhibited proliferation, migration and invasion of glioma cells, partially at least via suppressing ADAM9 expression. Therefore, miR-140 may be a novel candidate target for the development of therapeutic strategies for patients with glioma PMID: 27498787
    18. Increased ADAM9 mRNA expression is associated with esophageal adenocarcinoma. PMID: 27026568
    19. data reveal miR-590 as a tumor suppressor in NSCLC, which is at least partially mediated through targeting of ADAM9. Restoration of miR-590 may provide a promising therapeutic strategy for NSCLC. PMID: 27770372
    20. results suggested that miR-203 played tumor suppressive roles by downregulating ADAM9 and HULC and indicated its potential application in cancer treatment PMID: 26179263
    21. ADAM9 enhances CDCP1 protein expression by suppressing miR-218 for lung tumor metastasis PMID: 26553452
    22. ADAM9 and ROS1 are direct downstream targets of miR-33a PMID: 26507842
    23. Activation of ERalpha but not ERbeta increases ADAM9 expression in cultured human neuronal cells. PMID: 26592768
    24. miR-126 may act as a tumor suppressor via inhibition of cell invasion by downregulating ADAM9 in breast cancer development. PMID: 26261534
    25. This study has identified tenascin-C as a promoter of the invasiveness of brain tumor-initiating cells through a mechanism involving ADAM-9 proteolysis via the c-Jun NH2-terminal kinase pathway. PMID: 25646025
    26. Whole exome sequencing was performed, which identified a novel, homozygous mutation in ADAM9, c.967delT; p.Ser323Glnfs*33. PMID: 25546566
    27. ADAM9 silencing inhibits the tumor growth of non-small lung cancer in vitro and in vivo. PMID: 25778452
    28. ADAM9 plays an important role in gastric cancer proliferation and invasion, and that while expressed at high levels in some cancer cells that are responsive to functional inhibition and antitumor activity of a catalytic site-directed antibody. PMID: 25344581
    29. Given the significant correlation between tumor ADAM9 expression and serum RCAS1 concentration in both cervical and endometrial cancer as well as the role for ADAM9 in RCAS1 shedding. PMID: 25177692
    30. our data indicated that miR-126 inhibits cell growth, invasion, and migration of OS cells by downregulating ADAM-9. PMID: 25213697
    31. We identified a novel autosomal recessive ADAM9 mutation causing autosomal recessive cone-rod dystrophy (arCRD), anterior polar and posterior subcapsular cataract in a consanguineous Egyptian family. PMID: 25091951
    32. Results show how ADAM9 regulates lung cancer metastasis to the brain by facilitating the tPA-mediated cleavage of CDCP1. PMID: 25060522
    33. ADAM9 is expressed in an inducible fashion on PMN surfaces where it degrades some ECM proteins, and it promotes alveolar-capillary barrier injury during ALI PMID: 25063875
    34. ADAM9 up-regulates N-cadherin via miR-218 suppression in lung adenocarcinoma cells. PMID: 24705471
    35. this study describes the role of miR-126 in bladder cancer progression, identifying miR-126 and ADAM9 as potential clinical biomarkers of disease aggressiveness PMID: 24823697
    36. ADAM9 high expression is correlated positively and significantly with HDGF high expression in non-small cell lung cancer. PMID: 24770635
    37. The expression of circulating ADAM9 is down-regulated in pulmonary sarcoidosis. PMID: 23857158
    38. ADAM9 is an important molecule in the processes of invasion and metastasis. PMID: 23499592
    39. The over-expression of MGAM was confirmed with a 6.6 fold increase in expression at the mRNA level whereas the fold change in ADAM9 demonstrated a 1.6 fold increase. PMID: 23405089
    40. ADAM9 expression was low in castration resistant prostate cancer (CRPC), correlated with poor prognosis and might be involved in the succession from hormonal sensitive prostate cancer (HSPC) to CRPC by various functions. PMID: 23106877
    41. miR-126&126* restored expressions play a tumor suppressor role by directly regulating ADAM9 and MMP7 in melanoma. PMID: 23437250
    42. a novel molecular mechanism of ADAM9 in the regulation of prostate cancer cell proliferation. PMID: 23342005
    43. ADAM9 plays a crucial role in UV-induced EGFR activation and is overexpressed in skin cancer cell lines PMID: 19003995
    44. Transient transfection of ADAM9 and ACE cDNAs into HEK293 cells demonstrated that ADAM9 requires both membrane anchorage and its catalytic domain to shed ACE. PMID: 22480688
    45. The miR-126/ADAM9 axis plays essential role in the inhibition of invasive growth of pancreatic cancer cells. PMID: 22064652
    46. ADAM10 activity is regulated by inhibition of ADAM9, and this regulation may be used to control shedding of amyloid precursor protein by enhancing alpha-secretase activity, a key regulatory step in the etiology of Alzheimer disease PMID: 21956108
    47. ADAM-9 expression plays an important role in mediating cell-cell contacts between fibroblasts and melanoma cells and that these interactions contribute to proteolytic activities required during invasion of melanoma cells. PMID: 21135106
    48. The data of this suggested that promoter polymorphisms which regulate ADAM9 transcription are protective against SAD. PMID: 19237226
    49. ADAM9 plays a crucial role in prostate cancer progression and therapeutic resistance in part by altering E-cadherin and integrin expression. PMID: 20672324
    50. Secreted variants of ADAM9 are a key determinant in manifestation of aggressive migratory phenotypes associated with breast cancer progression. PMID: 20736367

    顯示更多

    收起更多

  • 相關(guān)疾病：
    Cone-rod dystrophy 9 (CORD9)
  • 亞細(xì)胞定位：
    [Isoform 1]: Cell membrane; Single-pass type I membrane protein.; [Isoform 2]: Secreted.
  • 組織特異性：
    Widely expressed. Expressed in chondrocytes. Isoform 2 is highly expressed in liver and heart.
  • 數(shù)據(jù)庫鏈接：

    HGNC: 216

    OMIM: 602713

    KEGG: hsa:8754

    STRING: 9606.ENSP00000419446

    UniGene: Hs.591852